Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TMEM269 divergent transcript (TMEM269-DT) is a long non-coding RNA (lncRNA) locus located on chromosome 1 (chr1:42775813-42784895, hg38) and also referred to as C1orf50-AS1 or C1orf50 antisense RNA 1[1]. Like other divergent antisense lncRNAs, TMEM269-DT is transcribed in the opposite direction from a nearby or overlapping protein-coding gene, in this case TMEM269 (which encodes a transmembrane protein). Divergent transcription of lncRNA/mRNA gene pairs is a widespread feature of active gene promoters in mammals and is believed to play a regulatory role in chromatin state and gene expression, particularly in developmentally important genes and transcription factors[3][4]. These lncRNAs often function in the nucleus, associating with chromatin and potentially influencing neighboring gene expression via RNA-mediated recruitment of chromatin-modifying complexes or formation of DNA-RNA hybrid (R-loop) structures; however, for TMEM269-DT, there is currently no published evidence of a well-defined molecular or disease role, and it is not considered a therapeutic target[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TMEM269 divergent transcript (TMEM269-DT).